Literature DB >> 2505792

The cytostatic effects of alpha-interferon may be mediated by transforming growth factor-beta.

D J Kerr1, I B Pragnell, A Sproul, S Cowan, T Murray, D George, R Leake.   

Abstract

There is some evidence to suggest that transforming growth factor-beta (TGF-beta) mediates the cytostatic effects of the anti-oestrogen tamoxifen. In this study we have demonstrated that alpha-interferon has a significant anti-proliferative effect on the oestrogen receptor-positive human breast cancer cell line ZR-75. There is decreased phenotypic expression of the oestrogen receptors (to about 30% of control values) and increased TGF-beta mRNA. Under the growth conditions used here, ZR-75 cells had approximately 5800 TGF-beta binding sites per cell, with an apparent dissociation constant of 70 pm, and we have shown that the anti-proliferative effects of alpha-interferon can be reduced by 60% by co-treating the cells with a TGF-beta polyclonal antibody. The cytostatic effects of alpha-interferon may therefore be mediated by TGF-beta in this human breast cancer cell line.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2505792     DOI: 10.1677/jme.0.0020131

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  3 in total

1.  Tamoxifen enhances interferon-regulated gene expression in breast cancer cells.

Authors:  D J Lindner; V Kolla; D V Kalvakolanu; E C Borden
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

2.  Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.

Authors:  D F Gibson; D A Johnson; D Goldstein; S M Langan-Fahey; E C Borden; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Gene expression in oestrogen-dependent human breast cancer xenograft tumours.

Authors:  A M Thompson; C M Steel; M E Foster; D Kerr; D Paterson; D Deane; R A Hawkins; D C Carter; H J Evans
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.